• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

A study aimed to elucidate the relationship between chemotherapy-induced oral mucositis (OM) and oral microbiota and establish preventive measures.

Research Project

Project/Area Number 19K07886
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 52010:General internal medicine-related
Research InstitutionUniversity of Toyama

Principal Investigator

Kajiura Shinya  富山大学, 学術研究部医学系, 講師 (70456383)

Project Period (FY) 2019-04-01 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2021: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2020: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2019: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Keywords化学療法 / 口内炎 / 口腔内細菌叢 / 乳酸菌製剤 / がん悪液質 / アナモレリン / プロバイオテクス / 腸内細菌叢 / 細菌叢
Outline of Research at the Start

当院で化学療法を行った症例について、化学療法中の口内炎を評価する。症例の唾液を採取し、口腔内細菌叢の評価を行い、口内炎の発生との関係を明らかにする。その後、口腔内乳酸菌を投与し、その口内炎予防効果との関係を明らかにする。口内炎の発生予防が、化学療法の治療効果と関係するかも推測する。

Outline of Final Research Achievements

We compared 16S rRNA analysis between chemotherapy-induced oral mucositis (OM) patients and non-OM patients to identify bacteria more prevalent in non-OM patients. Despite conducting retrospective analysis on chemotherapy-induced OM and supportive care, no correlation was found between lactobacillus preparations and OM. However, secondary analysis revealed that Anamorelin hydrochloride, a novel treatment for cancer cachexia, showed potential efficacy with prolonged administration during chemotherapy but not feasible in cases where chemotherapy became challenging. These findings were presented at the 5th International Conference on Palliative Care and accepted for publication in the Journal of Palliative Medicine.

Academic Significance and Societal Importance of the Research Achievements

化学療法起因性口内炎と口腔内細菌叢について、口内炎非発症者に多い細菌を同定したことで、化学療法起因性口内炎と口腔内細菌叢との関連が示唆される学術的意義がある。乳酸菌製剤によるプロバイオテクスによる化学療法起因性口内炎の治療に結びつくと推定したが、本後ろ向き研究では乳酸菌製剤と口内炎に相関は指摘できなかったが、今後の前向き研究の課題を得る意義はあった。副次的な検討ではあるが、がん悪液質の新規治療薬であるアナモレリン塩酸塩は、化学療法中にこそ投与が検討されるべきであるという学術的社会的意義のある結果が得られた。

Report

(6 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Research-status Report
  • 2021 Research-status Report
  • 2020 Research-status Report
  • 2019 Research-status Report
  • Research Products

    (3 results)

All 2024 2023

All Journal Article (1 results) (of which Peer Reviewed: 1 results) Presentation (2 results) (of which Int'l Joint Research: 1 results)

  • [Journal Article] Prescription Pattern of Anamorelin; a Therapeutic Agent for Cancer Cachexia2024

    • Author(s)
      Yoshihiro Tambo1, Shinya Kajiura, Akihiro Yoshida, Shingo Chikaoka, Yuki Tanabe, Nahoko Kanai, Ando Takayuki, Akira Ueda, Iori Moto, Yurika Nakayama, Tomoko Shima, Yukiko Matsusita, Tatsuji Mizukami, Mosaburou Kainuma, Ichiro Yasuda, Ryuji Hayashi
    • Journal Title

      Journal of Palliative Medicine

      Volume: -

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed
  • [Presentation] Prescription status of Anamorelin at Our Institution2023

    • Author(s)
      Shinya Kajiura, Yoshihiro Tambo, Akihiro Yoshida, Shingo Chikaoka, Nobukazu Ryu, Yuta Yagi, Ayaka Kadota, Sakie Fukai, Takako Matsushita, Naomi Hayashi, Miyuki Ichikawa, Nahoko Kanai, Yukiko Matsushita, Tatsuji Mizukami, Mosaburou Kainuma, Ryuji Hayashi
    • Organizer
      5th International Conference on Palliative Care
    • Related Report
      2023 Annual Research Report
    • Int'l Joint Research
  • [Presentation] 当院におけるアナモレリンの初期処方状況2023

    • Author(s)
      畝 好弘, 梶浦 新也, 吉田 明浩, 近岡 伸悟, 龍 伸和, 屋木 佑太, 門田 彩花, 深井 咲衣, 松下 孝子, 林 直美, 倉田 典子, 松下 有希子, 古市 厚志, 水上 達治, 貝沼 茂三郎, 林 龍二
    • Organizer
      第28回日本緩和医療学会
    • Related Report
      2023 Annual Research Report

URL: 

Published: 2019-04-18   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi